• 1
    Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20.
  • 2
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-730.
  • 3
    Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report–a phase iii multicenter, prospective, randomized trial (KLASS Trial). Ann Surg. 2010; 251: 417-420.
  • 4
    Ajani JA, Barthel JS, Bekaii-Saab T, et al; NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw. 2010; 8: 378-409.
  • 5
    Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009; 21: 1008-1015.
  • 6
    Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19: 3058-3065.
  • 7
    Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006; 24: 4692-4698.
  • 8
    Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8: 797-805.
  • 9
    Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000; 18: 3202-3210.
  • 10
    Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT. Detection of distant metastases in esophageal cancer with 18F-FDG PET. J Nucl Med. 2004; 45: 980-987.
  • 11
    Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004; 28: 247-253.
  • 12
    Koga H, Sasaki M, Kuwabara Y, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med. 2003; 17: 733-738.
  • 13
    Takahashi H, Ukawa K, Ohkawa N, et al. Significance of 18F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography. Ann Nucl Med. 2009; 23: 391-397.
  • 14
    Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006; 9: 192-196.
  • 15
    Kim EY, Lee WJ, Choi D, et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol. 2011; 79: 183-188.
  • 16
    Yang QM, Kawamura T, Itoh H, et al. Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology. 2008; 55: 782-785.
  • 17
    Lim JS, Kim MJ, Yun MJ, et al. Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma. Korean J Radiol. 2006; 7: 249-256.
  • 18
    Habermann CR, Weiss F, Riecken R, et al. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology. 2004; 230: 465-471.
  • 19
    Botet JF, Lightdale CJ, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology. 1991; 181: 426-432.
  • 20
    Catalano MF, Sivak MV Jr, Rice T, Gragg LA, Van Dam J. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc. 1994; 40: 442-446.
  • 21
    Greene FL Page DL, Fleming ID, et al, editors. AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors. 6th edition. New York, NY: Springer-Verlag; 2002.
  • 22
    Burke EC, Karpeh MS, Conlon KC, Brennan MF. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg. 1997; 225: 262-267.
  • 23
    Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006; 191: 134-138.
  • 24
    Power DG, Schattner MA, Gerdes H, et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg. 2009; 208: 173-178.
  • 25
    Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review. BMC Gastroenterol. 2011; 11: 19.
  • 26
    Duarte I, Llanos O. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol. 1981; 12: 237-242.
  • 27
    Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003; 30: 288-295.
  • 28
    Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. N Engl J Med. 2007; 357: 2277-2284.
  • 29
    Sarela AI, Yelluri S; for the Leeds Upper Gastrointestinal Cancer Multidisciplinary Team. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg. 2007; 142: 143-149.
  • 30
    Dalal K, Woo Y, Kelly K, et al. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer. 2008; 11: 206-213.
  • 31
    Keereweer S, Kerrebijn J, van Driel P, et al. Optical Image-guided Surgery-Where Do We Stand? Mol Imaging Biol. 2011; 13: 199-207.
  • 32
    Iwatsuki M, Fukagawa T, Mimori K, et al. Bone marrow and peripheral blood expression of ID1 in human gastric carcinoma patients is a bona fide indicator of lymph node and peritoneal metastasis. Br J Cancer. 2009; 100: 1937-1942.
  • 33
    Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008; 15: 3092-3100.